CLSA released a research report stating that WUXI XDC's (02268) second-half performance last year met expectations, while its 2026 guidance exceeded expectations. Management forecasts at least 35% revenue growth at constant exchange rates, including BioDlink, and at least 40% growth in CDMO revenue excluding BioDlink, with margins expected to remain largely stable year-on-year. The firm projects WUXI XDC's revenue growth from this year to 2028 to be 38%, 31%, and 28%, respectively. Net profit forecasts have been raised by 6% to 13%, and the target price has been increased from HK$70.7 to HK$80.9, with an "Outperform" rating reaffirmed. The report noted that WUXI XDC reiterated its target for an average annual revenue compound growth rate of 30% to 35% from 2025 to 2030, with a CMO portfolio target of 20% by 2030. Order backlog growth for 2025 is projected at 50%. CLSA believes this enhances the company's profit visibility and alleviates investor concerns about slowing growth.